1.	Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 19 and over Sponsor: Other Protocol IDs: UNMC-535-00, CDR0000069211, NCI-V02-1691, NCT00031642
2.	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02721, AMC-037, U01CA070019, CDR0000310158, NCT00064246
3.	Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: ID01-233, NCT00048737
4.	Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 51 to 75 Sponsor: Other Protocol IDs: CDR0000515982, KRDI-TUM-R-F-015-V-0030-I, EU-20633, NCT00397800
5.	CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: LS0382, 703-04, MAYO-LS0382, MAYO-IRB-703-04, NCT00438880
6.	Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: 2005-002206-37, NCT00302757
7.	Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 60 Sponsor: NCI, Other Protocol IDs: 98153, P30CA033572, P01CA030206, CHNMC-98153, CDR0000574716, NCT00562978
8.	Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NU 02H8, 1346001, NU-0228-024, PCI-P-PCYC-0213, NCT00089284
9.	Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 60 and over Sponsor: NCI, Other Protocol IDs: 02-090, MSKCC-02090, NCT00058422
10.	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000304498, CALGB-50201, SWOG-C50201, ECOG-C50201, NCT00062114
11.	S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000329864, U10CA032102, S0313, SWOG-S0313, NCT00070018
12.	Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: ID01-541, NCT00038623
13.	Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 04-251, NCT00119730
14.	Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: Z-BEAM, NCT00138086
15.	Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: Ritux plus TNI, NCT00147953
16.	Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: SCRI LYM 27, 106-P092, NCT00193505
17.	Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: No age limit Sponsor: Other Protocol IDs: ID03-0287, NCT00290511
18.	Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 64 and under Sponsor: Other Protocol IDs: AMC 2005-276, NCT00336843
19.	The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: TH011101, NCT00440583
20.	Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2005-0512, NCT00493467
21.	Targeted Intensification Utilizing ZBEAM Followed by Autologous Stem Cell Transplantation (ASCT) in Patients With High-grade B-Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: ZBEAM2, EUDRACT: 2007-000270-23, NCT00689169
22.	Zevalin® First Line in Follicular Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: Over 50 Sponsor: Other Protocol IDs: EudraCT-No.:2006-005778-34, PEI-No.: 364/01, BFS-No.: 22461/2-2007-001, NCT00772655
23.	Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: 2005-002003-17, NCT00514475
24.	Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 1726.00, NCI-2010-01381, FHCRC-1726.00, 5787, NCT00119392
25.	Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000334470, ECOG-E1499, E1499, NCT00070447